COMMUNIQUÉS West-GlobeNewswire

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
11/03/2024
Study will inform on long-term safety profile and tissue frataxin levels OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp Frataxin data and safety data from the OLE study are intended to help [...]
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
11/03/2024
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA™ in [...]
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
11/03/2024
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® ( [...]
LifeMD Reports Fourth Quarter 2023 Results
11/03/2024
Fourth quarter revenue increased 60% year-over-year to $44.9 million with Telehealth revenues increasing 90% versus the year-ago period. Adjusted EPS of $0.15 per share compared with $0.02 in the year-ago period. [...]
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/03/2024
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified [...]
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
11/03/2024
Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of [...]
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
11/03/2024
March 13 webcast showcasing Quelimmune ™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com DENVER, March 11, 2024 (GLOBE NEWSWIRE) -- [...]
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
11/03/2024
FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
11/03/2024
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3 monotherapy trial in Q4 [...]
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
11/03/2024
BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare [...]
Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
11/03/2024
Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of $20 to $30 Million LAKE FOREST, Il., [...]
Teknova Reports Fourth Quarter and Full Year 2023 Financial Results
11/03/2024
Full year 2023 total revenue was $36.7 million, down 11% year-over-year Achieved 36% annual growth in the number of Clinical Solutions customers in 2023 Company provides 2024 revenue guidance of $35-38 million HOLLISTER [...]
Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference
11/03/2024
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced that Pete Anevski, Progyny’s Chief Executive [...]
MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders
11/03/2024
This is a first-of-its-kind training for any major American municipality. MAPS uses its over 30 years of experience in the psychedelic space to offer a gold-standard training program. MAPS looks to share this training [...]
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment
11/03/2024
The OASIS trial is a first-in-class clinical trial combining a CD19-expressing oncolytic virus, which flags solid tumours for attack by CD19-targeting therapeutics such as Amgen’s Blincyto ® , Gilead’s Yescarta ® and [...]
medac unveils new Global Corporate Brand
11/03/2024
WEDEL, Germany, March 11, 2024 (GLOBE NEWSWIRE) -- The pharmaceutical company medac, founded in Germany in 1970, has evolved into an internationally renowned corporate group with two contract development and [...]
AMN Healthcare Enhances Internal Resource Pool Management for Health Systems with Vendor Neutral Technology Capabilities
11/03/2024
DALLAS, March 11, 2024 (GLOBE NEWSWIRE) -- In response to the healthcare industry’s increasing needs for innovative workforce solutions, AMN Healthcare, the leader in total talent solutions for healthcare organizations [...]
Signia Expands Integrated Xperience (IX) Platform Portfolio with Addition of Discreet, Design-Forward Styletto IX and Insio IX Hearing Aids that Directly Challenge Hearing Aid Stigma
11/03/2024
Two additional hearing aid form factors join the award-winning Integrated Xperience platform, offering patients an expanded range of solutions that deliver unprecedented speech clarity and intelligibility in group [...]
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11/03/2024
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The corrected release [...]

Pages